Navigation Links
QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
Date:10/12/2010

loys nearly 90,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

QIAGEN Safe Harbour Statement

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including fluctuations due to the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Co
'/>"/>

SOURCE QIAGEN
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
2. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
3. QIAGEN Acquires Exclusive Licence for Key PI3K gene
4. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
5. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
6. Plexus Awarded Development Contract With QIAGEN
7. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
8. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
9. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
10. SciQuest Announces Strategic Alliance with QIAGEN
11. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 A novel robotic system that ... is currently being tested as part of a biomedical ... Boston with the aim of determining if the robot, ... cancer biopsies faster, more accurate, less costly, and less ... the potential to deliver prostate cancer therapies with greater ...
(Date:9/18/2014)... 2014 Research and Markets has ... Stem Cell Industry Report, 2014-2017" report to their ... cells that can differentiate into specialized cells and can ... cell therapy can be applied to treatment of cardiovascular ... system diseases, damage or lesion of liver, kidney and ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014  U.S. biotech ... by signing an exclusive license for technology developed by ... control gene expression in plants, including for applications in ... The technology was developed under the ... officer at Kultevat and former president of the Danforth ...
(Date:9/18/2014)... 18, 2014   Sigma-Aldrich Corporation (Nasdaq: ... entered into a new gene editing partnership with ... Core. Under the partnership, Sigma-Aldrich will provide the ... consultation, and dedicated gene editing bioinformaticians. ... research at the U-M Medical School. One initiative ...
Breaking Biology Technology:Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Kultevat obtains license of gene switch technology 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... perfect example of the wonders of nanotechnology, in which common ... new and exciting possibilities. , Graphene ... graphitic carbon, which is used to make the pigment that ... to a one-atom-thick sheet. Graphene is among the strongest materials ...
... will result in over $80 million reduction in 2009 ... Pharmaceuticals,Inc. (Nasdaq: AMLN ) today announced a corporate ... 25 percent, or 340,employees, and reduce anticipated 2009 cash ... reduction are part of the,Company,s business plan to be ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) announced today financial ... 30, 2008., Third Quarter and Nine Months Financial ... months ended Sept. 30, 2008, was,$3.8 million and $12.2 ... in 2007. Revenue in the third quarter and nine,months ...
Cached Biology Technology:Researchers discover method for mass production of nanomaterial graphene 2Researchers discover method for mass production of nanomaterial graphene 3Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction 2Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 6
(Date:9/18/2014)... developed a unique method to use microbes buried in ... , The first microbe-powered, self-sustaining wastewater treatment system ... clean up waste from large farming operations and rural ... Haluk Beyenal and graduate student Timothy Ewing in the ... in the online edition of Journal of Power ...
(Date:9/18/2014)... can operate inside the bore of an MRI scanner ... research partnership program at Brigham and Women,s Hospital in ... in conjunction with real-time MRI images, can make prostate ... discomforting for the patient. The novel system also has ... precision. , Developed by a team of robotics engineers ...
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... UC Davis cancer researchers have found that older men ... regular CT scans over lymph node removal are at ... last week in the journal Cancer, indicate that physicians ... when discussing treatment options with their patients. ...
... University of Washington physicists are detecting radioactivity from ... a mammoth March 11 earthquake, but the levels are ... health. On March 16, the scientists began testing ... Building on the UW campus, looking for evidence of ...
... is available in German . , Innovations relating ... presented by KIT at the 2011 Hannover Messe from April ... KIT will present a hybrid Porsche racing car, developments in ... InnoEnergy for a European energy supply system, and the Energy ...
Cached Biology News:Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 3Physicists detect low-level radioactivity from Japan arriving in Seattle 2Physicists detect low-level radioactivity from Japan arriving in Seattle 3KIT presents innovations at the 2011 Hannover Messe 2KIT presents innovations at the 2011 Hannover Messe 3KIT presents innovations at the 2011 Hannover Messe 4KIT presents innovations at the 2011 Hannover Messe 5
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... System is used in conjunction ... PCR of problematic and/or GC-rich ... Solution with 10X PCRX Amplification ... broader magnesium concentration broader annealing ...
MAGP-2 (C-19)...
Biology Products: